FrieslandCampina Ingredients secures Aequival 2’-FL approval for infant milk formulas in Thailand

The Thai FDA’s approval of 2′-FL enables more brands to utilise functional ingredients for more infants and children

FrieslandCampina Ingredients has announced the regulatory approval of its 2’-Fucosyllactose (2’-FL) ingredient. Aequival 2’-FL can now be added to infant milk formulas and follow-up formulas in Thailand.

Following its previous approval for flavoured milk drinks for children of three years and above, Aequival 2’-FL is permitted for use in products for infants and younger children too. With this development, the company’s human milk oligosaccharide (HMO) ingredient becomes accessible to the whole early life nutrition category in the country. This also makes FrieslandCampina Ingredients the only provider of both HMOs and GOS (galacto-oligosaccharides) in Thailand, which, when used together, may offer complementary health benefits.

Brand owners can utilise 2’-FL in combination with GOS for their product formulations. Interest in, and use of, 2’-FL in infant milk formula (IMF) is particularly on the rise in Thailand. In 2023, nearly 15% of new IMF product launches in the country were supplemented with 2’-FL.

“Thailand’s early life nutrition market is thriving, particularly for children – a commonly overlooked area, but we anticipate a 20% volume growth in this specific segment by 2030 in this country. We previously secured approval for 2’-FL to be used in flavoured milk drinks and developed concept applications such as ready-to-drink beverages for kids aged three upwards – there has been great feedback from our customers and consumers,” stated Sophie Nicolas, global marketing lead of early life nutrition at FrieslandCampina Ingredients. “This latest approval is not only exciting due to the advantages our HMOs can deliver in infant milk formula, but also because Aequival 2’-FL can now be used across the full early life nutrition category, from newborns to kids.”

HMOs are the third largest component of human milk, and 2’-FL is the most abundant of these HMOs. With scientific evidence corroborating the ingredient’s efficacy for supporting gut health, emerging research continues to substantiate 2’-FL’s ability to deliver this and a range of other benefits for infant development, including brain development, cognition and learning. The Thai FDA’s approval of Aequival 2’-FL for infant milk formulas coincides with growing consumer recognition of the importance of gut health and increasing demand for ingredients with science-backed benefits.

“Science shows that 2’-FL can play a vital role in supporting health in infancy and childhood, thanks in part to its bifidogenic effects. But this is just one example of the benefits offered by 2’-FL and oligosaccharides more widely,” continued Nicolas. “We believe including other prebiotic ingredients alongside 2’-FL, such as our Vivinal GOS, could offer even more benefits by providing more diverse oligosaccharides structures in recipes. This, in turn, unlocks exciting opportunities for our customers in Thailand and the many other markets where Aequival 2’-FL and Vivinal GOS are available.”